Equities

Profound Medical Corp

PRN:TOR

Profound Medical Corp

Actions
Health CareMedical Equipment and Services
  • Price (CAD)11.24
  • Today's Change-0.08 / -0.71%
  • Shares traded4.84k
  • 1 Year change-8.24%
  • Beta0.8937
Data delayed at least 15 minutes, as of Nov 13 2024 20:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

  • Revenue in CAD (TTM)12.57m
  • Net income in CAD-43.93m
  • Incorporated2014
  • Employees131.00
  • Location
    Profound Medical Corp2400 Skymark Ave Unit 6MISSISSAUGA L4W 5K5CanadaCAN
  • Phone+1 (647) 476-1350
  • Fax+1 (647) 476-1350
  • Websitehttps://profoundmedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medmira Inc383.32k-3.11m57.66m65.00------150.43-0.0045-0.00450.0006-0.0240.07520.74310.2848---61.10-69.95----62.6166.76-812.38-187.610.2112-1.96-----54.57-5.98-46.08------
Theralase Technologies Inc920.62k-4.41m63.60m0.00--41.15--69.08-0.0195-0.01950.00410.00690.27220.7672.65---130.29-69.79-204.79-81.7849.0037.49-478.72-557.680.7723--0.1707---6.00-9.2012.69---22.53--
Sernova Corp0.00-38.93m74.82m-----------0.1283-0.12830.00-0.04130.00-------191.48-74.84-693.32-85.03---------------------59.69---2.91--
Covalon Technologies Ltd29.20m-823.40k97.26m----4.04773.533.33-0.0335-0.03351.180.87861.101.775.15---3.11-18.06-3.72-27.1056.4551.89-2.82-27.063.72-21.120.0474--46.56-0.09651.79--12.21--
Healwell Al Inc25.69m-19.99m271.88m340.00--4.43--10.59-0.1667-0.15650.20480.36580.3316--5.63---26.98-35.09-46.26-56.2744.4532.02-81.35-44.56---8.560.2053---29.81-30.48-75.82---19.23--
Profound Medical Corp12.57m-43.93m277.20m131.00--6.38--22.05-1.87-1.870.53151.760.19390.49241.3595,984.78-67.74-38.41-77.69-41.9562.0250.32-349.41-387.155.16--0.167--7.7529.090.3488------
Hamilton Thorne Ltd101.58m-2.37m340.09m----3.9052.673.35-0.0158-0.01580.67170.57450.72922.648.29---1.701.50-2.061.7850.6850.84-2.342.181.070.89780.2919--15.5518.14-131.77--26.56--
Vitalhub Corp58.32m4.75m574.10m353.00106.024.5058.329.840.10350.10351.242.440.393733.413.20165,218.403.210.30554.380.391581.4880.008.140.7272.15--0.00310.0031.3741.94274.55--1.09--
Data as of Nov 13 2024. Currency figures normalised to Profound Medical Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.